Últimas noticias sobre Eledon Pharma (NASDAQ:ELDN) Bolsa

Eledon Pharma

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals Inc

WIIM

IRBT

iRobot shares are trading lower after the company disclosed substantial doubt about its ability to continue as a going concern.

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) from Neutral to Neutral.

News

Reiteration

Analyst Ratings

GERN

HC Wainwright & Co. Reiterates Neutral on Geronto Neutral

Heinz Launched Dip For Potato Chips, Same Unmistakable Ketchup, New Way To Enjoy

SFIX

Stitch Fix shares are trading higher following strong Q2 earnings and upbeat Q3 guidance.

GRPN

Groupon shares are trading higher after the company reported better-than-expected Q4 revenue results.

Needham analyst Ryan Koontz maintains Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) with a Buy and lowers the price target from $95 to $90.

Price Target

CIEN

Needham Maintains Buy on Ciena, Lowers Price Target to $90

Rosenblatt analyst Blair Abernethy upgrades Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) from Neutral to Buy and announces $77 price target.

Upgrades

RBRK

Rosenblatt Upgrades Rubrik to Buy, Announces $77 Price Target

TSLA

Tesla shares are trading higher after CEO Elon Musk on social media announced plans to double US vehicle production within two years.

Whitestone REIT Announced That It Has Signed A Lease With The Picklr To Open A 20,909-square-foot Location At Terravita Marketplace In Scottsdale, Arizona

STEC

Santech Holdings Regains NASDAQ Compliance, Closes Chapter On Minimum Bid Price Violation

TLRY

Tilray Beverages Announced The Distribution Expansion For Runner's High Brewing, Its Non-alcoholic Craft Beer Brand, Across 4,500 New Distribution Points

INTC: 9% &#x7C; <a href="https://www.benzinga.com//node/44271204">TSMC Proposes Joint Venture With Nvidia, AMD And Broadcom To Operate Intel's Factories: Report</a>
&nbsp;
GRPN: 27% &#x7C; <a href="https://www.benzinga.com//node/44262868">Groupon shares are trading higher after the company reported better-than-expected Q4 revenue results.</a>
&nbsp;
SFIX: 24% &#x7C; <a href="https://www.benzinga.com//node/44262293">Stitch Fix shares are trading higher following strong Q2 earnings and upbeat Q3 guidance.</a>

Movers

Trading Ideas

INTC

Market-Moving News for March 12th

Intel shares are trading higher following a report suggesting TSMC pitched a joint venture to Nvidia, AMD, Broadcom and Qualcomm to operate Intel's factories.

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Immunocore Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) with a Buy and maintains $100 price target.

IMCR

HC Wainwright & Co. Reiterates Buy on Immunocore Holdings, Maintains $100 Price Target

Q1 2025 Guidance
Given the prevailing uncertainty in NIH funding and academic research purchasing, along with normal seasonality, the Company expects Q1 2025 revenues of $19 million to $21 million and gross margin in the 56% to 58% range.

Guidance

HBIO

Harvard Bioscience Expects Q1 Revenue Of $19M-$21M Vs $22.95M Est

Piper Sandler analyst Derek Podhaizer assumes Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) with a Overweight rating and announces Price Target of $22.

Initiation

AESI

Piper Sandler Assumes Atlas Energy Solutions at Overweight, Announces Price Target of $22

HC Wainwright &amp; Co. analyst Sean Lee maintains Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) with a Buy and raises the price target from $7.5 to $9.5.

HC Wainwright & Co. Maintains Buy on Myomo, Raises Price Target to $9.5

TRNR

Interactive Strength Inc.  Secures $3.6M in 3-Year Notes From Institutional Investor, Following $2.9M Investment

Earnings

VNET

VNET Q4 EPADS $(0.01) Misses $0.03 Estimate, Sales $307.75M Beat $284.88M Estimate

For the full-year 2025, which will set the stage to become a pure-play Power company, we currently expect:
<ul>
<li>Consolidated revenue from continuing operations to grow mid-to-high single digit year-over-year as compared with equivalent revenue of $185.8 million in 2024.</li>
<li>Consolidated gross profit margin from continuing operations between 19.5% to 21.5%, reflecting the fact that we have completed the wind down of Transitional Foundry Services and new generation power products will just begin production in the second half 2025. The equivalent gross profit margin was 21.5% in 2024.</li>
</ul>

Magnachip Expects FY25 Revenue Growth From Continuing Operations Of Mid-To-High Single Digit Vs $185.8M YoY

Press Releases

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

General

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

ELDN

Abeona Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Eledon Pharma

Noticias

Últimas noticias sobre Eledon Pharma (NASDAQ:ELDN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL